Bezwoda W R, Golombick T, Dansey R, Keeping J
Department of Medicine, University of the Witwatersrand Medical School, Johannesburg, South Africa.
Eur J Cancer. 1991;27(11):1423-9. doi: 10.1016/0277-5379(91)90024-8.
Intraperitoneal treatment with interferon (IFN) for malignant ascites due to advanced ovarian carcinoma refractory to chemotherapy gave an objective response rate of 36% (7/19 patients treated). In vitro studies demonstrated that cytotoxicity of peripheral blood monocytes/macrophages was stimulated by IFN. However, peritoneal exudate cells obtained after intraperitoneal treatment with interferon were not stimulated to kill autologous tumour cells. Clinical response was therefore most probably due to a direct inhibitory effect of IFN on growth of malignant cells rather than due to an immune modulatory effect. Using a newly established ovarian cancer cell line (UWOV1), synergy between the growth inhibitory/antitumour effects of IFN and cisplatin was demonstrated at clinically achievable concentrations of each agent. IFN plus cisplatin proved to be more effective than intraperitoneal cisplatin alone in control of peritoneal carcinomatosis. The response rate was 5/7 (77%) for combined modality therapy vs. 2/9 (22%) for intraperitoneal chemotherapy alone. Both in vitro and in vivo studies suggest a role for interperitoneal therapy for control of refractory ascites in ovarian cancer.
对化疗难治的晚期卵巢癌所致恶性腹水进行腹腔内干扰素（IFN）治疗，客观缓解率为36%（19例接受治疗的患者中有7例）。体外研究表明，IFN可刺激外周血单核细胞/巨噬细胞的细胞毒性。然而，腹腔内注射干扰素治疗后获得的腹腔渗出细胞未被刺激以杀伤自体肿瘤细胞。因此，临床反应很可能是由于IFN对恶性细胞生长的直接抑制作用，而非免疫调节作用。使用新建立的卵巢癌细胞系（UWOV1），在每种药物临床可达到的浓度下，证实了IFN和顺铂的生长抑制/抗肿瘤作用之间具有协同作用。IFN加顺铂在控制腹膜癌转移方面比单独腹腔内使用顺铂更有效。联合治疗的缓解率为5/7（77%），而单纯腹腔化疗的缓解率为2/9（22%）。体外和体内研究均提示腹腔内治疗在控制卵巢癌难治性腹水中的作用。
